drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (dendritic cell cancer vaccine)
drug_description
Autologous dendritic cell-based cancer vaccine generated from the patient's leukapheresis; dendritic cells are loaded with multi-epitope folate receptor‑alpha peptides and administered intradermally to prime FRα‑specific CD8+ and CD4+ T-cell responses and antibodies against FRα‑expressing tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Neoplasm Vaccines
drug_category
DC VACCINE
drug_class
Vaccine
drug_delivery_route
Intradermal
drug_mechanism_of_action
Autologous dendritic cells are loaded ex vivo with multi-epitope folate receptor‑alpha peptides and administered intradermally. The DCs migrate to draining lymph nodes and present FRα peptides on MHC I and II to activate FRα‑specific CD8+ cytotoxic and CD4+ helper T cells and induce antibodies, leading to immune‑mediated killing of FRα‑expressing tumor cells and potential epitope spreading.
drug_name
Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine (FRαDCs)
nct_id_drug_ref
NCT06639074